Simple heteroaryl modifications in the 4,5-diarylisoxazol-3-carboxylic acid scaffold favorably modulates the activity as dual mPGES-1/5-LO inhibitors with in vivo efficacy


Gurses T., OLĞAÇ A. , Garscha U., GÜR MAZ Z. T. , BAL N. B. , Uludag O. , ...More

BIOORGANIC CHEMISTRY, vol.112, 2021 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 112
  • Publication Date: 2021
  • Doi Number: 10.1016/j.bioorg.2021.104861
  • Title of Journal : BIOORGANIC CHEMISTRY
  • Keywords: E2 synthase-1, 5-lipoxygenase, 5-lipoxygenase-activating protein, Isoxazole, Inflammation, PROSTAGLANDIN E-2 SYNTHASE-1, 5-LIPOXYGENASE-ACTIVATING PROTEIN FLAP, LEUKOTRIENE BIOSYNTHESIS, ACCURATE DOCKING, NEW-GENERATION, DISCOVERY, IDENTIFICATION, DERIVATIVES, COMPLEX, ENZYME

Abstract

Microsomal prostaglandin E2 synthase-1 (mPGES-1), 5-lipoxygenase (5-LO) and 5- lipoxygenase-activating protein (FLAP) are key for biosynthesis of proinflammatory lipid mediators and pharmacologically relevant drug targets. In the present study, we made an attempt to explore the role of small heteroaromatic fragments on the 4,5-diarylisoxazol-3-carboxylic acid scaffold, which are selected to interact with focused regions in the active sites of mPGES-1, 5-LO and FLAP. We report that the simple structural variations on the benzyloxyaryl side-arm of the scaffold significantly influence the selectivity against mPGES-1, 5-LO and FLAP, enabling to produce multitarget inhibitors of these protein targets, exemplified by compound 18 (IC50 mPGES-1 = 0.16 mu M; IC50 5-LO = 0.39 mu M) with in vivo efficacy in animal model of inflammation. The computationally modeled binding structures of these new inhibitors for three targets provide clues for rational design of modified structures as multi-target inhibitors. In conclusion, the simple synthetic procedure, and the possibility of enhancing the potency of this class of inhibitors through structural modifications pave the way for further development of new multi-target inhibitors against mPGES-1, 5-LO and FLAP, with potential application as anti-inflammatory agents.